局限期前列腺癌超大分割与中度大分割放疗的疗效与毒性比较:倾向评分分析
本研究纳入421例局限期前列腺癌患者,比较超大分割放疗(EH-RT,6.5-7 Gy/次,总剂量32.5-35 Gy)与中度大分割放疗(MH-RT,26次2.7 Gy,总剂量70.2 Gy)的疗效与毒性。倾向评分匹配后226例分析显示,EH-RT组急性及晚期泌尿生殖毒性和胃肠道毒性风险更低,肿瘤学结局无显著差异。
要点
- EH-RT较MH-RT显著降低>1级急性泌尿生殖和胃肠道毒性风险。
- 倾向评分匹配后两组的肿瘤学结局(生化控制、总生存等)无统计学显著差异。
- EH-RT或可作为特定局限期前列腺癌患者的优选治疗模式。
核心结论
- EH-RT较MH-RT降低急性和晚期毒性风险,且肿瘤学结局相当。
- 数据提示EH-RT或可作为特定局限期前列腺癌患者的优选治疗模式。
研究设计与样本
- 回顾性比较分析,共纳入421例局限期前列腺癌患者,MH-RT组227例(中位随访43个月),EH-RT组194例(中位随访30个月)。
- 采用倾向评分匹配创建可比队列,匹配后226例纳入分析。
- 使用多因素比例风险Cox模型比较两组毒性及肿瘤学结局。
主要发现
- 全人群分析中,MH-RT组>1级急性泌尿生殖毒性显著更常见(P < .001)。
- 全人群分析中,MH-RT组>1级急性胃肠道毒性显著更常见(P < .002)。
- 多因素分析显示晚期泌尿生殖毒性在MH-RT组有边缘显著增高(P = .07)。
- 肿瘤学结局方面未观察到统计学显著差异。
- 倾向评分匹配后结果与全人群分析一致。
关键数值与推荐
- EH-RT方案:分次剂量6.5-7 Gy,总剂量32.5-35 Gy。
- MH-RT方案:26次,每次2.7 Gy,总剂量70.2 Gy。
- 急性>1级泌尿生殖毒性MH-RT组更常见,P < .001。
- 急性>1级胃肠道毒性MH-RT组更常见,P < .002。
- 晚期泌尿生殖毒性多因素分析P = .07。
临床怎么用
- 对于选择合适局限期前列腺癌患者,EH-RT可考虑作为治疗选择之一。
- EH-RT在保持肿瘤学结局相当的同时可能降低急性及晚期毒性风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare clinical outcomes and toxicities of 2 radiation therapy (RT) schemes for localized prostate cancer (PCa): extreme hypofractionation (EH; fractions of 6.5-7 Gy to a total dose of 32.5-35 Gy) and the moderate hypofractionation (MH; 26 fractions of 2.7 Gy to a total dose of 70.2 Gy). A propensity score method was used to compare the EH-RT and MH-RT groups. METHODS AND MATERIALS: Our analysis included a total of 421 patients divided in 2 groups: 227 treated with MH-RT and 194 treated with EH-RT (43 and 30 months median follow-up, respectively). Propensity matching created comparable cohorts. Statistical evaluations were performed on the whole cohort, stratifying the analyses by risk strata factors identified with the propensity scores, and on a subgroup of patients matched by propensity score. Multivariate proportional hazard Cox models were used to compare the 2 groups, mainly for gastrointestinal and genitourinary toxicity and secondarily for clinical progression-free survival, biochemical progression-free survival, and overall survival. RESULTS: Considering the whole population, acute genitourinary and gastrointestinal greater than grade 1 was significantly more frequent in the whole MH-RT group (P < .001 and P < .002, respectively). A borderline significantly greater late genitourinary was confirmed with the multivariate analysis (P = .07). Concerning tumor outcome, no statistically significant differences were observed. After propensity score matching, 226 patients were included in the analysis. The 2 obtained propensity score matched groups did not differ for any of the clinical and pathologic variables considered for the analysis, resulting in well-balanced cohorts. The results obtained on the whole population were confirmed in the matched groups. CONCLUSIONS: EH-RT yields a decreased risk of acute or late toxicities compared with MH-RT, and oncologic outcomes were comparable. Our data indicate that EH-RT might be considered as a treatment modality of choice for select patients with PCa.
引用
- Marvaso G, Ciardo D, Gandini S, et al. Comparison of Outcomes and Toxicity Between Extreme and Moderate Radiation Therapy Hypofractionation in Localized Prostate Cancer: A Propensity Score Analysis. Int J Radiat Oncol Biol Phys. 2019. PMID: 31377161. doi:10.1016/j.ijrobp.2019.07.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。